FDA "Drug Watch" Website To Include Three Categories Of Safety Information
This article was originally published in The Pink Sheet Daily
Executive Summary
The site will reflect information about serious adverse events, patient selection and monitoring, and risk minimization procedures, an FDA draft guidance states. Manufacturers will be notified "shortly before" information about a drug is first posted; agency suggests the site's information will not be used for promotional purposes.
You may also be interested in...
CDER Abandons “Drug Watch” Program To Communicate Safety In Favor Of Asterisk
FDA issues final guidance describing its approach to communicating drug safety information, including emerging information, to the public.
CDER Abandons “Drug Watch” Program To Communicate Safety In Favor Of Asterisk
FDA issues final guidance describing its approach to communicating drug safety information, including emerging information, to the public.
MedWatch Bulletin For Physicians Under Consideration At FDA
The report would be similar to CDC’s Morbidity & Mortality Weekly Report, Deputy Commissioner Gottlieb says.